Pasireotide: all 56 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Study of Pasireotide in People With ProlactinomaRecruitingNCT06295952Phase 2
• Pasireotide LAR Therapy of Silent Corticotroph Pituitary TumorsTerminatedNCT02749227Phase 2Results posted
• Safety and Efficacy Study of SOM230 s.c. in Cluster HeadacheTerminatedNCT02619617Phase 2Results posted
• Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesCompletedNCT02354508Phase 3Results posted
• Pasireotide in Prevention of GI ToxicityCompletedNCT02215070Phase 2Results posted
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4Results posted
• Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary GigantismCompletedNCT01673646Phase 2Results posted
• Pasireotide LAR in Severe Polycystic Liver DiseaseCompletedNCT01670110Phase 2Results posted
• Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT01639352Phase 2Results posted
• Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping SyndromeCompletedNCT01637272Phase 2Results posted
• Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasCompletedNCT01620138Phase 2/3Results posted
• 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialCompletedNCT01563354Phase 2Results posted
• Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT01488487Phase 2Results posted
• Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT01468532Phase 1/2Results posted
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNETTerminatedNCT01374451Phase 2Results posted
• Breast Cancer Chemoprevention by SOM230, an IGF-I Action InhibitorTerminatedNCT01372618Phase 1/2Results posted
• Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.CompletedNCT01283542Phase 2Results posted
• Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid CancerCompletedNCT01270321Phase 2Results posted
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyCompletedNCT01137682Phase 3Results posted
• Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male VolunteersCompletedNCT01128192Phase 2Results posted
• Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and AbscessCompletedNCT00994110Phase 3Results posted
• Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginTerminatedNCT00958841Phase 2Results posted
• Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph AdenomasTerminatedNCT00929669Phase 2Results posted
• Phase II Study of SOM230 in Patients With Recurrent or Progressive MeningiomaTerminatedNCT00813592Phase 2Results posted
• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid DiseaseCompletedNCT00690430Phase 3Results posted
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3Results posted
• Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 3Results posted
• Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCompletedNCT00171951Phase 2Results posted
• An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With AcromegalyCompletedNCT00171730Phase 2Results posted
• Study Evaluating SOM230 in Patients With Metastatic Carcinoid TumorsCompletedNCT00088595Phase 2Results posted
• Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal CarcinomatosisTerminatedNCT04826432Phase 2
• A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310CompletedNCT03847207Phase 1
• Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass SurgeryStatus unknownNCT03514576Phase 4
• Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic HypoglycemiaCompletedNCT03103009Phase 1
• Adipokine Profile in Patients With Cushing's Disease on Pasireotide TreatmentCompletedNCT03080181Phase 4
• Pasireotide in Hyperinsulinemic HypoglycemiaWithdrawnNCT03053284Phase 2
• SOM230 Ectopic ACTH-producing TumorsWithdrawnNCT02780882Phase 2
• Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
• Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical TreatmentCompletedNCT02713776Phase 2
• Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment FailureCompletedNCT02622906Phase 2
• Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping SyndromeCompletedNCT01895296Phase 2
• Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate CancerCompletedNCT01646684Phase 1
• Pasireotide Therapy in Patients With Nelson's SyndromeTerminatedNCT01617733Phase 2
• A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy VolunteersCompletedNCT01578928Phase 1
• Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic MetastasesCompletedNCT01469572Phase 1
• Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung CancerStatus unknownNCT01417806Phase 2
• Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle TrialCompletedNCT01372644Phase 1
• Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)CompletedNCT01364415Phase 1
• Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast CancerCompletedNCT01356862Phase 2
• SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaWithdrawnNCT01329289Phase 2
• IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor EverolimusWithdrawnNCT01234974Phase 2
• Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT00804336Phase 1
• Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic FunctionCompletedNCT00698464Phase 1
• Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid DiseaseCompletedNCT00446082Phase 1
• A Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseCompletedNCT00088608Phase 2
• Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsCompletedNCT00088582Phase 2

← Pasireotide overview